Literature DB >> 8965678

Analysis of human parainfluenza virus 3 receptor binding variants: evidence for the use of a specific sialic acid-containing receptor.

A Moscona1, R W Peluso.   

Abstract

In order for the fusion protein (F) of the human parainfluenza virus type 3 (HPF3) to promote membrane fusion and viral entry, the haemagglutinin-neuraminidase (HN) glycoprotein must interact with its receptor. Sialoglycoconjugates are known to be the receptors for the HPF3 HN, however specific attachment factors or receptors for HPF3 have not been identified. In this report we describe the analysis of variants of HPF3 with increased fusion-promoting phenotypes that were selected by treatment with viral neuraminidase. The results suggest that for HPF3, the virus is specific in its use of sialic acid receptors; the majority of sialic-acid containing molecules are not targets for HPF3.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8965678     DOI: 10.1006/mpat.1996.0016

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  10 in total

1.  A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo.

Authors:  Anne Moscona; Matteo Porotto; Samantha Palmer; Caroline Tai; Lori Aschenbrenner; Gallen Triana-Baltzer; Qi-Xiang Li; David Wurtman; Stefan Niewiesk; Fang Fang
Journal:  J Infect Dis       Date:  2010-07-15       Impact factor: 5.226

2.  A second receptor binding site on human parainfluenza virus type 3 hemagglutinin-neuraminidase contributes to activation of the fusion mechanism.

Authors:  Matteo Porotto; Micaela Fornabaio; Glen E Kellogg; Anne Moscona
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

3.  Contribution of the human parainfluenza virus type 3 HN-receptor interaction to pathogenesis in vivo.

Authors:  G A Prince; M G Ottolini; A Moscona
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

4.  Human parainfluenza virus type 3 HN-receptor interaction: effect of 4-guanidino-Neu5Ac2en on a neuraminidase-deficient variant.

Authors:  M Porotto; O Greengard; N Poltoratskaia; M A Horga; A Moscona
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

5.  Regulation of Viral RNA Synthesis by the V Protein of Parainfluenza Virus 5.

Authors:  Yang Yang; James Zengel; Minghao Sun; Katrina Sleeman; Khalid Amine Timani; Jason Aligo; Paul Rota; Jianguo Wu; Biao He
Journal:  J Virol       Date:  2015-09-16       Impact factor: 5.103

6.  Human parainfluenza 3 and respiratory syncytial viruses detected in pangolins.

Authors:  Tengcheng Que; Jing Li; Yugan He; Panyu Chen; Wei Lin; Meihong He; Lei Yu; Aiqiong Wu; Luohao Tan; Yingjiao Li; Yanling Hu; Yigang Tong
Journal:  Emerg Microbes Infect       Date:  2022-12       Impact factor: 19.568

7.  Role of nucleolin in human parainfluenza virus type 3 infection of human lung epithelial cells.

Authors:  Santanu Bose; Mausumi Basu; Amiya K Banerjee
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

8.  Akt plays a critical role in replication of nonsegmented negative-stranded RNA viruses.

Authors:  Minghao Sun; Sandra M Fuentes; Khalid Timani; Dengyun Sun; Chris Murphy; Yuan Lin; Avery August; Michael N Teng; Biao He
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

9.  Human parainfluenza virus evolution during lung infection of immunocompromised individuals promotes viral persistence.

Authors:  Alexander L Greninger; Ksenia Rybkina; Michelle J Lin; Jennifer Drew-Bear; Tara C Marcink; Ryan C Shean; Negar Makhsous; Michael Boeckh; Olivia Harder; Francesca Bovier; Shana R Burstein; Stefan Niewiesk; Bert K Rima; Matteo Porotto; Anne Moscona
Journal:  J Clin Invest       Date:  2021-12-01       Impact factor: 19.456

10.  The Sialic Acid Binding Activity of Human Parainfluenza Virus 3 and Mumps Virus Glycoproteins Enhances the Adherence of Group B Streptococci to HEp-2 Cells.

Authors:  Jie Tong; Yuguang Fu; Fandan Meng; Nadine Krüger; Peter Valentin-Weigand; Georg Herrler
Journal:  Front Cell Infect Microbiol       Date:  2018-08-17       Impact factor: 5.293

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.